MYR Pharma在欧洲肝脏研究协会（EASL）会议上宣布多次演讲

StephenW

MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting

News provided by
MYR Pharma

Mar 27, 2018, 10:21 ET

Share this article

BURGWEDEL, Germany, March 27, 2018 /PRNewswire/ -- MYR Pharma GmbH, focused on the development of Myrcludex B, a novel drug for the treatment of Hepatitis B and Delta, today announced a number of oral and poster presentations at the upcoming International Liver Congress organized by the European Association for the Study of the Liver (EASL) in Paris, France. The presentations are scheduled as follows:

Oral Presentations

    Heiner Wedemeyer, "Final Results of a Multicenter, Open-Label Phase 2b Clinical Trial to Assess Safety and Efficacy of Myrcludex B in Combination with Tenofovir in Patients with Chronic HBV/HDV Co-Infection", GS-005, General Session I and opening ceremony (Main Plenary), April 12, 3:00-3:15pm.

    Lena Allweiss, "Strong Intrahepatic Decline of Hepatitis D Virus RNA and Antigen After 24 Weeks of Treatment with Myrcludex B in Combination with Tenofovir in Chronic HBV/HDV Infected Patients: Interim Results from a Multicenter, Open-Label Phase 2b Clinical Trial", PS-162, Parallel session: HBV and HDV: Current and Emerging Treatments (South 4), April 14, 9:30-9:45am.

Poster Presentations

    Mathias Haag, "Bile Acid Monitoring to Support Safety and Efficacy of Myrcludex B in Combination with Tenofovir in Patients with Chronic HBV/HDV Co-Infection", FRI-353, Session: Viral Hepatitis B/D: Therapy, April 13, 9:00am to 5:00pm.

    Katrin Schöneweis, "Reduction of Serum Infectivity of Hepatitis Delta Virus- Infected Patients Treated with Myrcludex B: An in vitro Assay to Determine Infectious Units", SAT-3, Session: Viral Hepatitis A,B,C,D,E : Virology, April 14, 9:00am-5:00pm

An additional presentation will be given at the 15th Hepatitis Delta International Network (HDIN) Meeting during EASL:

    Alexander Alexandrov, "Myrcludex B, a Novel Entry Inhibitor for Treatment of HBV/HDV Infection: Overview of the Clinical Development Status", Congress Center Room WEST 3, April 11, 7:25-7:35pm.

About Myrcludex  B

Myrcludex B is a first-in-class entry inhibitor for the treatment of chronic hepatitis B (HBV) and its co-infection hepatitis Delta. The drug has received Orphan Designation for treatment of HDV infection from the EMA and FDA, and PRIME scheme eligibility from the EMA.

To find out more about Myrcludex B, visit http://myr-pharma.com/science/about-myrcludex-b.

StephenW

MYR Pharma在欧洲肝脏研究协会（EASL）会议上宣布多次演讲

新闻提供
MYR Pharma

2018年3月27日，东部时间10:21

分享此文章

新泽西州BURGWEDEL，2018年3月27日电/新华美通/ - MYR Pharma GmbH，专注于开发治疗乙型肝炎和三角洲的新型药物Myrcludex B，今天在即将到来的国际肝脏大会上宣布了一系列口头和海报介绍大会由法国巴黎欧洲肝脏研究协会（EASL）组织。演讲安排如下：

口头演讲

Heiner Wedemeyer，“评估Myrcludex B联合替诺福韦治疗慢性HBV / HDV合并感染患者的安全性和有效性的多中心开放性2b期临床试验的最终结果”，GS-005，第一次会议并开幕仪式（主要全体会议），4月12日，下午3：00-3：15。

Lena Allweiss，“Myrcludex B联合替诺福韦治疗慢性HBV / HDV感染患者24周后肝炎病毒RNA和抗原的强烈肝内降低：多中心开放标签2b期临床试验的临时结果”，PS -162，平行会议：HBV和HDV：当前和新兴治疗（南4），4月14日，9：30-9：45上午。

海报演示文稿

Mathias Haag，“胆汁酸监测支持Myrcludex B联合替诺福韦治疗慢性HBV / HDV共感染患者的安全性和疗效”，FRI-353，Session：Viral Hepatitis B / D：Therapy，April 13，9：上午00时至下午5时。

KatrinSchöneweis，“降低用Myrcludex B处理的肝炎三角洲病毒感染患者的血清感染性：用于确定传染单位的体外测定法”，SAT-3，课程：病毒性甲型肝炎，B，C，D，E：病毒学， 4月14日上午9:00至下午5:00

在EASL第15届国际肝炎三角洲国际网络（HDIN）会议上将另外发表演讲：

亚历山大·亚历山德罗夫，“Myrcludex B，HBV / HDV感染治疗的新型进入抑制剂：临床发展状态概述”，会议中心室西3，4月11日，7：25-7：35 pm。

关于Myrcludex B

Myrcludex B是治疗慢性乙型肝炎（HBV）及其合并感染性肝炎三角洲的一流入门抑制剂。该药物已获得孤儿指定用于治疗来自EMA和FDA的HDV感染，以及PRIME计划资格来自EMA。

要了解有关Myrcludex B的更多信息，请访问http://myr-pharma.com/science/about-myrcludex-b。

齐欢畅

马克

桦子

新型药物Myrcludex B抑制剂联合替诺福韦治疗慢性HBV / HDV感染患者多中心开放性2b期临床试验结果：24周后肝炎病毒RNA和抗原的强烈肝内降低。